Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main near-term catalyst is navacaprant, an experimental depression treatment being tested in patients with major depressive disorder. On May 7, Neumora said two late-stage studies, KOASTAL-2 and KOASTAL-3, were fully enrolled in the first quarter of 2026, with more than 400 patients in each trial. The company expects to report combined top-line results from the two studies in the second quarter of 2026, making the update a major test of the stock’s bull case.

Neumora is also trying to build a broader brain-disease pipeline beyond navacaprant. The company said NMRA-511 remains on track to report data in the second half of 2026 from a study in agitation linked to Alzheimer’s disease, with a Phase 2 trial expected to begin in the first quarter of 2027. Another drug candidate, NMRA-898, is being tested in healthy volunteers and patients with stable schizophrenia, with Phase 1 data also expected in the second half of 2026. Neumora ended the first quarter with $147.1 million in cash and cash equivalents, which it expects to fund operations into the third quarter of 2027.

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company developing treatments for brain diseases, including depression, Alzheimer’s-related agitation, and schizophrenia.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.